Vasopressin during Laparoscopic Myomectomy: Does It Really Extend Its Limits?

Area of Science:

• Gynecologic Surgery
• Minimally Invasive Procedures
• Surgical Pharmacology

Background:

• Laparoscopic myomectomy is a common procedure for uterine fibroids.
• Expansion of indications requires safe and effective surgical techniques.
• Minimizing intraoperative blood loss is crucial for patient safety and surgical success.

Purpose of the Study:

• To evaluate the role of vasopressin in enhancing the safety of laparoscopic myomectomy.
• To determine if vasopressin reduces blood loss and complications.
• To assess the impact of vasopressin on procedure length and patient outcomes.

Main Methods:

• Retrospective comparison of prospectively collected data from 150 patients undergoing laparoscopic myomectomy.
• Group 1 (n=50): no vasoconstrictive agent.
• Group 2 (n=100): intraoperative intramyometrial vasopressin injection.

Main Results:

• Mean estimated blood loss (EBL) was significantly lower in the vasopressin group (147.8 mL) compared to the control group (321.8 mL) (p <.001).
• Fewer laparoconversions (0% vs 4%) and lower rates of hypercapnea and subcutaneous emphysema were observed in the vasopressin group.
• Procedure length and serious cardiovascular adverse events did not differ significantly; risk factors for longer procedures included myoma size and number.

Conclusions:

• Intramyometrial vasopressin is effective in reducing blood loss during laparoscopic myomectomy.
• Vasopressin use may contribute to safer expansion of laparoscopic myomectomy indications by minimizing blood loss and certain complications.
• While experienced surgeons can manage operation times, vasopressin offers significant blood loss reduction, especially in complex cases.